Your browser doesn't support javascript.
loading
HLA Class I Analysis Provides Insight Into the Genetic and Epigenetic Background of Immune Evasion in Colorectal Cancer With High Microsatellite Instability.
Kawazu, Masahito; Ueno, Toshihide; Saeki, Koichi; Sax, Nicolas; Togashi, Yosuke; Kanaseki, Takayuki; Chida, Keigo; Kishigami, Fumishi; Sato, Kazuhito; Kojima, Shinya; Otsuka, Masafumi; Kawazoe, Akihito; Nishinakamura, Hitomi; Yuka, Maeda; Yamamoto, Yoko; Yamashita, Kazuo; Inoue, Satoshi; Tanegashima, Tokiyoshi; Matsubara, Daisuke; Tane, Kenta; Tanaka, Yosuke; Iinuma, Hisae; Hashiguchi, Yojiro; Hazama, Shoichi; Khor, Seik-Soon; Tokunaga, Katsushi; Tsuboi, Masahiro; Niki, Toshiro; Eto, Masatoshi; Shitara, Kohei; Torigoe, Toshihiko; Ishihara, Soichiro; Aburatani, Hiroyuki; Haeno, Hiroshi; Nishikawa, Hiroyoshi; Mano, Hiroyuki.
Afiliación
  • Kawazu M; Division of Cellular Signaling, National Cancer Center Research Institute, Tokyo, Japan. Electronic address: mkawz-tky@umin.ac.jp.
  • Ueno T; Division of Cellular Signaling, National Cancer Center Research Institute, Tokyo, Japan.
  • Saeki K; Department of Computational Biology and Medical Sciences, Graduate School of Frontier Sciences, The University of Tokyo, Chiba, Japan.
  • Sax N; KOTAI Biotechnologies, Inc, Osaka Japan.
  • Togashi Y; Division of Cancer Immunology, Research Institute, Exploratory Oncology Research and Clinical Trial Center, National Cancer Center, Tokyo, Japan.
  • Kanaseki T; Department of Pathology, School of Medicine, Sapporo Medical University, Sapporo, Japan.
  • Chida K; Department of Gastrointestinal Oncology, National Cancer Center Hospital East, Chiba, Japan.
  • Kishigami F; Division of Cellular Signaling, National Cancer Center Research Institute, Tokyo, Japan; Department of Surgical Oncology, The University of Tokyo, Tokyo, Japan.
  • Sato K; Department of Surgical Oncology, The University of Tokyo, Tokyo, Japan.
  • Kojima S; Division of Cellular Signaling, National Cancer Center Research Institute, Tokyo, Japan.
  • Otsuka M; Division of Cellular Signaling, National Cancer Center Research Institute, Tokyo, Japan.
  • Kawazoe A; Division of Cancer Immunology, Research Institute, Exploratory Oncology Research and Clinical Trial Center, National Cancer Center, Tokyo, Japan; Department of Gastrointestinal Oncology, National Cancer Center Hospital East, Chiba, Japan.
  • Nishinakamura H; Division of Cancer Immunology, Research Institute, Exploratory Oncology Research and Clinical Trial Center, National Cancer Center, Tokyo, Japan.
  • Yuka M; Division of Cancer Immunology, Research Institute, Exploratory Oncology Research and Clinical Trial Center, National Cancer Center, Tokyo, Japan.
  • Yamamoto Y; Department of Surgical Oncology, The University of Tokyo, Tokyo, Japan.
  • Yamashita K; KOTAI Biotechnologies, Inc, Osaka Japan.
  • Inoue S; Division of Cellular Signaling, National Cancer Center Research Institute, Tokyo, Japan.
  • Tanegashima T; Division of Cancer Immunology, Research Institute, Exploratory Oncology Research and Clinical Trial Center, National Cancer Center, Tokyo, Japan; Department of Urology, Graduate School of Medical Sciences, Kyushu University, Fukuoka, Japan.
  • Matsubara D; Division of Integrative Pathology, Jichi Medical University, Shimotsukeshi, Japan.
  • Tane K; Division of Cancer Immunology, Research Institute, Exploratory Oncology Research and Clinical Trial Center, National Cancer Center, Tokyo, Japan; Department of Thoracic Surgery, National Cancer Center Hospital East, Chiba, Japan.
  • Tanaka Y; Division of Cellular Signaling, National Cancer Center Research Institute, Tokyo, Japan.
  • Iinuma H; Department of Surgery, Teikyo University School of Medicine, Tokyo, Japan.
  • Hashiguchi Y; Department of Surgery, Teikyo University School of Medicine, Tokyo, Japan.
  • Hazama S; Department of Digestive Surgery and Surgical Oncology, Yamaguchi University Graduate School of Medicine, Yamaguchi, Japan.
  • Khor SS; Department of Human Genetics, Graduate School of Medicine, The University of Tokyo, Tokyo, Japan.
  • Tokunaga K; Department of Human Genetics, Graduate School of Medicine, The University of Tokyo, Tokyo, Japan.
  • Tsuboi M; Department of Thoracic Surgery, National Cancer Center Hospital East, Chiba, Japan.
  • Niki T; Division of Integrative Pathology, Jichi Medical University, Shimotsukeshi, Japan.
  • Eto M; Department of Urology, Graduate School of Medical Sciences, Kyushu University, Fukuoka, Japan.
  • Shitara K; Department of Gastrointestinal Oncology, National Cancer Center Hospital East, Chiba, Japan.
  • Torigoe T; Department of Pathology, School of Medicine, Sapporo Medical University, Sapporo, Japan.
  • Ishihara S; Department of Surgical Oncology, The University of Tokyo, Tokyo, Japan.
  • Aburatani H; Genome Science Division, Research Center for Advanced Science and Technologies, The University of Tokyo, Tokyo, Japan.
  • Haeno H; Department of Computational Biology and Medical Sciences, Graduate School of Frontier Sciences, The University of Tokyo, Chiba, Japan.
  • Nishikawa H; Division of Cancer Immunology, Research Institute, Exploratory Oncology Research and Clinical Trial Center, National Cancer Center, Tokyo, Japan; Department of Immunology, Nagoya University Graduate School of Medicine, Nagoya, Japan.
  • Mano H; Division of Cellular Signaling, National Cancer Center Research Institute, Tokyo, Japan; Research Institute, National Cancer Center Research Institute, Tokyo, Japan.
Gastroenterology ; 162(3): 799-812, 2022 03.
Article en En | MEDLINE | ID: mdl-34687740
ABSTRACT
BACKGROUND &

AIMS:

A detailed understanding of antitumor immunity is essential for optimal cancer immune therapy. Although defective mutations in the B2M and HLA-ABC genes, which encode molecules essential for antigen presentation, have been reported in several studies, the effects of these defects on tumor immunity have not been quantitatively evaluated.

METHODS:

Mutations in HLA-ABC genes were analyzed in 114 microsatellite instability-high colorectal cancers using a long-read sequencer. The data were further analyzed in combination with whole-exome sequencing, transcriptome sequencing, DNA methylation array, and immunohistochemistry data.

RESULTS:

We detected 101 truncating mutations in 57 tumors (50%) and loss of 61 alleles in 21 tumors (18%). Based on the integrated analysis that enabled the immunologic subclassification of microsatellite instability-high colorectal cancers, we identified a subtype of tumors in which lymphocyte infiltration was reduced, partly due to reduced expression of HLA-ABC genes in the absence of apparent genetic alterations. Survival time of patients with such tumors was shorter than in patients with other tumor types. Paradoxically, tumor mutation burden was highest in the subtype, suggesting that the immunogenic effect of accumulating mutations was counterbalanced by mutations that weakened immunoreactivity. Various genetic and epigenetic alterations, including frameshift mutations in RFX5 and promoter methylation of PSMB8 and HLA-A, converged on reduced expression of HLA-ABC genes.

CONCLUSIONS:

Our detailed immunogenomic analysis provides information that will facilitate the improvement and development of cancer immunotherapy.
Asunto(s)
Palabras clave

Texto completo: 1 Banco de datos: MEDLINE Asunto principal: Genes MHC Clase I / Neoplasias Colorrectales / Microglobulina beta-2 / Escape del Tumor Tipo de estudio: Prognostic_studies Límite: Humans Idioma: En Año: 2022 Tipo del documento: Article

Texto completo: 1 Banco de datos: MEDLINE Asunto principal: Genes MHC Clase I / Neoplasias Colorrectales / Microglobulina beta-2 / Escape del Tumor Tipo de estudio: Prognostic_studies Límite: Humans Idioma: En Año: 2022 Tipo del documento: Article